Who is sponsoring NCT04605419?

NCT04605419 is sponsored by Michael Patrick Achiam.

What drugs are being tested in NCT04605419?

Interventions in NCT04605419: Calcium electroporation.

What condition does NCT04605419 study?

NCT04605419 studies Barretts Esophagus With High Grade Dysplasia.

Is NCT04605419 still recruiting?

NCT04605419 is currently status unknown. Last updated 28 October 2020.

Last reviewed 2020-10-28 · How we verify

NCT04605419

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Calcium Electroporation in Patients With Cell Changes in the Esophagus

Status unknown Phase 1 Last updated 28 October 2020

What this trial tests

Phase 1 trial testing Calcium electroporation in Barretts Esophagus With High Grade Dysplasia in 6 participants. Status unknown.

Timeline

7 October 2020

Primary endpoint
1 September 2021

1 September 2021

Quick facts

Lead sponsor	Michael Patrick Achiam
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	7 October 2020
Primary completion	1 September 2021
Estimated completion	1 September 2021
Sites	1 location across Denmark

Drugs / interventions tested

Calcium electroporation — full drug profile →

Conditions studied

Barretts Esophagus With High Grade Dysplasia — all drugs for Barretts Esophagus With High Grade Dysplasia →

Sponsor

Michael Patrick Achiam

Who can join

18 and older, any sex, with Barretts Esophagus With High Grade Dysplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this first-in-man study is to evaluate the safety of calcium electroporation used in patients with Barrett's esophagus high-grade dysplasia through an endoscopic system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Calcium electroporation

Trials testing the same drug.

NCT05609656 — Electroporation and Immunotherapy in Metastatic Colorectal Cancer · Phase 2 · terminated
NCT04259658 — Histopathologic Effect of Calcium Electroporation on Cancer in the Skin · Phase 2 · completed
NCT04225767 — Calcium Electroporation as a Treatment for Cutaneous and Subcutaneous Malignant Tumours · Phase 2 · unknown
NCT03694080 — Calcium Electroporation for Early Colorectal Cancer · Phase 1 · unknown
NCT03542214 — Calcium Electroporation for the Treatment of Colorectal Cancer · Phase 1 · completed

Other Michael Patrick Achiam trials

Trials by the same sponsor.

NCT04958044 — Endoscopic Assisted Calcium Electroporation in Esophageal Cancer · Phase 1 · completed
NCT04669951 — Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04605419 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michael Patrick Achiam
Last refreshed: 28 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04605419.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing